You searched for side effects - Page 59 of 311 - Medivizor
Navigation Menu

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Posted by on Apr 18, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of pyrotinib (SHR-1258) plus capecitabine (Xeloda) versus lapatinib (Tyverb) plus capecitabine in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data...

Read More

Can using ultra-rapid lispro in patients with type 1 diabetes using subcutaneous insulin infusion improve glucose control after meals?

Can using ultra-rapid lispro in patients with type 1 diabetes using subcutaneous insulin infusion improve glucose control after meals?

Posted by on Apr 11, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness and safety of ultra-rapid lispro (URLi; LyumjevTM) to lispro (Humalog) in patients with type 1 diabetes (T1D) on continuous subcutaneous insulin infusion (CSII). The authors concluded that URLi was similarly effective and provided improved postprandial glucose (PPG) control with reduced hypoglycemia in...

Read More

Tibial nerve stimulation improves urinary symptoms in patients with Parkinson´s disease

Tibial nerve stimulation improves urinary symptoms in patients with Parkinson´s disease

Posted by on Apr 11, 2021 in Parkinson's Disease | 0 comments

In a nutshell This study investigated the effectiveness of percutaneous tibial nerve stimulation (PTNS) treatment in patients with Parkinson's disease (PD) and lower urinary tract symptoms (LUTS). Researchers suggested that PTNS is associated with improved outcomes in these patients. Some background PD is a chronic disease that affects over...

Read More

Comparing nilotinib and dasatinib as second line treatment in patients with chronic myeloid leukemia in a real-life setting

Comparing nilotinib and dasatinib as second line treatment in patients with chronic myeloid leukemia in a real-life setting

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare dasatinib (Sprycel) and nilotinib (Tasigna) as second-line treatments for patients with chronic-phase (CP) chronic myeloid leukemia (CML) in a real-life setting.   This study concluded that both dasatinib and nilotinib are equally effective and well...

Read More

Evaluating treatment options after surgery for patients with high-risk melanoma.

Evaluating treatment options after surgery for patients with high-risk melanoma.

Posted by on Apr 11, 2021 in Melanoma | 0 comments

In a nutshell The aim of this study was to evaluate different types of therapy after surgery for patients with high-risk melanoma. The study found that add-on targeted therapy or immunotherapy was likely to decrease the risk of disease progression in these patients. Some background Melanoma is a form of skin cancer. Treatment for early-stage...

Read More

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Posted by on Apr 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate if the VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) regimen in combination with immunotherapy was effective as a salvage therapy for patients with relapsed or refractory (r/r) multiple myeloma (MM). The study found this salvage therapy option...

Read More

Can Vitamin B12 improve nerve function in patients with diabetes and nerve dysfunction?

Can Vitamin B12 improve nerve function in patients with diabetes and nerve dysfunction?

Posted by on Apr 11, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the effectiveness of vitamin B12 in people with type 2 diabetes (T2D) and loss of nerve function. It found that the vitamin improved pain, sensation, and quality of life in these patients. Some background T2D is a condition that involves high levels of glucose (sugar) in the blood. Over time, high blood sugar can...

Read More

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

Posted by on Apr 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL).   The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...

Read More